FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in ...

The philanthropic arm of a major pharmaceutical company gave several Dallas-based nonprofits hundreds of thousands of dollars ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

xGen™ HIV Amplicon Panel provides a single-tube, 2.5-hour workflow designed to enable detection down to 1,000 viral genome copies “This launch represents one of the many ways IDT is continuing to ...

The Journey to a Vaccine,” a new documentary, premiered at Boston’s Museum of Science. The premiere was preceded by a ...

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at ...

During his 36-year career at Fred Hutch Cancer Center, Michael Emerman, PhD, made fundamental discoveries about HIV, the retrovirus that causes AIDS. He and Fred Hutch evolutionary biologist Harmit ...

Researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine have discovered how a specific type of immune cell may contribute to the persistence of HIV ...